Comprehensive management of cardiovascular risk. Focusing on telmisartan

Czech version

Authors: R. Češka; S. Krutská; L. Zlatohlávek; M. Vráblík
Authors‘ workplace: Centrum preventivní kardiologie III. interní kliniky 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in: Vnitř Lék 2010; 56(8): 839-844
Category: 50th Birthday - Jindřich Špinar, MD, CSc., FESC

Overview

Cardiovascular diseases (CVD) represent a significant health problem in all countries world‑wide and in the developed world, including the Czech Republic, in particular. The underlying cause in the majority of CVD patients is atherosclerosis and its complications, respectively. The present paper focuses on prevention and timely treatment of atherosclerosis. Management should be comprehensive and should target the risk factors (RF). Hypertension, hyperlipoproteinaemia and dyslipidemia (HLP and DLP), type 2 diabetes mellitus (T2DM), visceral fat obesity and cigarette smoking are the dominating RFs. Even though all RFs have to be managed simultaneously and it is not possible to focus on just one of them, for the sake of clarity, this paper discusses hypertension and the use of telmisartan, a representative of one the most up‑to‑date group of antihypertensives. There is a growing evidence that it is not always just a reduction of a specific risk that is important but also the mode of treatment. For example, to reduce a CV risk in a patient with hypertension but also, for example, with metabolic syndrome, it is more beneficial to treat the patient with rennin‑angiotensin system (RAS) blocking agents, possibly in a combination with calcium channels antagonists, than to use “traditional” (older) treatment approach with a combination of a beta/blocker and diuretic. Among the RAS‑modifying agents, ACE inhibitors and sartans are the most widely used. Among sartans, telmisartan is very well‑tolerated and has evidence from a large interventional study for its effect on reducing the CV risk.

Key words:
cardiovascular diseases – global risk – hypertension – dyslipidaemia – metabolic syndrome – antihypertensives – telmisartan – hypolipidemic agents – statins – metformin

Sources

1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta‑analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.

2. Fait T, Vrablík M, Češka R. Preventivní medicína. Praha: Maxdorf 2008.

3. Fruchart JCh, Sacks F, Hermans MP et al for the Residual Risk Reduction Initiative (R3i). The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia, Am J Cardiol 2008; 102 (Suppl): 1K–34K.

4. Fruchart JCh, Sacks F, Hermans MP et al for the Residual Risk Reduction Initiative (R3i). The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. Diabetes and Vasc Dis Res 2008; 5: 319–325.

5. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists and other blood pressure lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 355: 1955–1964.

6. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta‑analysis of randomised trials. BMJ 2008; 336: 1121–1123.

7. Dahlöf B, Sever PS, Poulter NR et al for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo‑Scandinavian Cardiac Outcomes Trial‑Blood Pressure Lowering Arm (ASCOT‑BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.

8. Jamerson K, Weber MA, Bakris GL et al for the ACCOMPLISH trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high‑risk patients. N Engl J Med 2008; 359: 2417–2428.

9. HOPE (Heart Outcomes Prevention Evaluation) Study Investigators. Effects of an angiotensin‑converting‑enzyme inhibitor, ramipril, on cardiovascular events in high‑risk patients. N Engl J Med 2000; 342: 145–153.

10. PROGRESS Collaborative Group. Randomised trial of a perindopril‑based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041.

11. Bultas J. Blokátory systému renin‑angiotenzin‑aldosteron v sekundární prevenci cévních mozkových příhod. Remedia 2009; 19: 138–142.

12. Boutitie F, Oprisiu R, Achard JM et al. Does a change in angiotensin II formativ caused by antihypertensive drugs affect the risk of stroke? A meta‑analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens 2007; 25: 1543–1553.

13. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–1559.

14. The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin‑receptor blocker telmisartan on cardiovascular events in high‑risk patients intolerant to angiotensin‑converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–1183.

15. Yusuf S, Diener HC, Sacco RL et al for the PRoFESS study group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225–1237.

16. Widimský jr. J, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2007. Doporučení České společnosti pro hypertenzi. Vnitř Lék 2008; 54: 101–118.

17. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta‑analysis on 11,000 participants from 42 trials. Am J Med 2009, 122: 290–300.

18. Williams B, Lacy PS, Thom SM et al for the CAFE and ASCOT Investigators. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation study: the CAFE Study. Circulation 2006; 113: 1213–1225.

19. Rothwell PM, Howard SC, Dolan E et al. Effects of blockers and calcium‑channel blockers on within‑individual variability in blood pressure and risk of stroke. Lancet Neurol 2010. Available from www.lancet.com/neurology.

20. Williams B. Hypertension and the „J‑curve“. JACC 2009; 54: 1834–1835.

21. The Accord Study Group. Effects of intensit blood‑pressure control in type 2 diabetes mellitus. N Engl J Med 2010; Mar 14. Available from www.nejm.org.

22. Executive summary of the third report of the NCEP expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001; 285: 2486–2497.

23. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342: 1040–1042.

24. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687–1697.

25. Češka R. Cholesterol a ateroskleróza. Léčba dyslipidémií. Praha: Triton 2005.

26. Ballantyne C et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography in ASTEROID. Circulation 2008; DOI: 10.1161/CIRCULATIONAHA.108.773747.

27. Robins SJ, Collins D, Wittes JT et al. Relation of gemfibrozil treatment and lipid levels with major coronary events, VA‑HIT: A randomized controlled trial. JAMA 2001; 285: 1585–1591.

28. Jones PH, Davidson MH, Stein EA et al. Comparison of the Efficacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin and Pravastatin Across Doses (STELLAR Trial). Am J Cardiol 2003; 93: 152–160.

29. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoproteid cholesterol, ischaemic heart disease and stroke: systematic review and meta‑analysis, BMJ 2003; 326: 1–7.

30. Keating GM, Robinson DM. Rosuvastatin. A review of its effect on atherosclerosis. Am J Cardiovasc Drugs 2008; 8: 127–146.